Marie-Paule Kieny | |
|---|---|
 | |
| Nationality | French |
| Alma mater | University of Montpellier; University of Strasbourg |
Marie-Paule Kieny is a French virologist, vaccinologist, public health expert and science writer. She is currently director of research at INSERM and chief of the board at DNDi.
Kieny completed her PhD in microbiology in 1980 at the University of Montpellier, and received her Habilitation à Diriger des Recherches in 1995 from the University of Strasbourg. [1]
Kieny was presented with an honorary doctorate from the Autonomous University of Barcelona in 2019 for her commitment to public health and worldwide universal health care. [2] [3] [4] [5]
After completing her PhD, Kieny took up a position at Transgene SA, Strasbourg, as assistant scientific director under scientific director Jean-Pierre Lecocq until 1988. [1]
Kieny became director of research at Inserm for the first time between 1999 and 2000. [1] Kieny was a member of the European Vaccine Initiative until 2010. [6]
Kieny was vaccine research director of WHO from 2002 to 2010, most notably during the 2009 swine flu pandemic. [7] [8] She was promoted to assistant director-general, playing a major leadership role during the Ebola virus epidemic in West Africa and the 2015–16 Zika virus epidemic. [1] [9] [10] [11] [12] Kieny even audaciously signed up herself as a test subject for the safety of new Ebola vaccines being developed, amidst concerns over the logistics and ethics of testing early-stage therapeutics and preventatives for ebola in the context of an ongoing epidemic. [13] [14] Given the slow development of new therapies in response to the outbreak, Kieny and colleagues began making a framework to speed up development and encourage researchers to share data openly without worrying about being scooped. [15] She commented on the successful development of efficacious vaccines for deployment in a future outbreak. [16] In aftermath of the 2014 Democratic Republic of the Congo Ebola virus outbreak Kieny stated that the vaccine may not be required since the outbreak was not as serious as previously feared. [17] Kieny was involved also in addressing the ongoing antimicrobial resistance crisis with WHO, overseeing the first WHO Model List of Essential Medicines to include guidance on proper use of antibiotics within the framework of universal health care. [11] [18] She helped prepare a list of Antibiotic resistant bacteria which should be prioritised for research beyond just Extensively drug-resistant tuberculosis, such as Acinetobacter baumannii and Pseudomonas aeruginosa strains resistant to Carbapenem . [19] [20] [21]
Kieny was one of seven vaccine experts interviewed in 2012 by Wired about what the next decade held for vaccine innovation. [22]
In 2017 she joined the board of directors for the Human Vaccines Project, was made interim director of the Medicines Patent Pool (MPP), and joined the Drugs for Neglected Diseases Initiative (DNDi) as chief of the board. [8] [10] [23] [24] [25] As head of MPP, Kieny oversaw the licensing of the Hepatitis C drug Mavyret for generic production. [26] [27]
Sir Richard Brook Sykes is a British microbiologist, the chair of the Royal Institution, the UK Stem Cell Foundation, and the trustees at King Edward VII's Hospital, and chancellor of Brunel University. As of June 2021, he is chair of the UK's Vaccine Taskforce, where he is responsible for overseeing the delivery of the COVID-19 vaccination programme, including preparations for booster programmes and encouraging vaccine innovation in the UK.
The Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients' needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases, notably leishmaniasis, sleeping sickness, Chagas disease, malaria, filarial diseases, mycetoma, paediatric HIV, cryptococcal meningitis, hepatitis C, and dengue. DNDi's malaria activities were transferred to Medicines for Malaria Venture (MMV) in 2015.
Mirta Roses Periago is an Argentine epidemiologist who served as Director of the Pan American Health Organization (PAHO) from 2003 until 2013.
The Biomedical Advanced Research and Development Authority (BARDA)' is a U.S. Department of Health and Human Services (HHS) office responsible for the procurement and development of medical countermeasures, principally against bioterrorism, including chemical, biological, radiological and nuclear (CBRN) threats, as well as pandemic influenza and emerging diseases. BARDA was established in 2006 through the Pandemic and All-Hazards Preparedness Act (PAHPA) and reports to the Office of the Assistant Secretary for Preparedness and Response (ASPR). The office manages Project BioShield, which funds the research, development and stockpiling of vaccines and treatments that the government could use during public health emergencies such as chemical, biological, radiological or nuclear (CBRN) attacks.
Margaret Ann "Peggy" Hamburg is an American physician and public health administrator, who is serving as the chair of the board of the American Association for the Advancement of Science (AAAS) and co-chair of the InterAcademy Partnership (IAP). She served as the 21st Commissioner of the U.S. Food and Drug Administration from May 2009 to April 2015.
Sir Jeremy James Farrar is a British medical researcher who has served as Chief Scientist at the World Health Organization since 2023. He was previously the director of The Wellcome Trust from 2013 to 2023 and a professor of tropical medicine at the University of Oxford.
Firdausi Qadri is a Bangladeshi scientist with specialization in immunology and infectious disease research. She has worked over 25 years on the development of vaccines for cholera and has expertise on other infectious disease like ETEC, Typhoid, Helicobacter pylori, rotavirus, etc. Currently, she is working as a director for Centre for Vaccine Sciences of International Centre for Diarrhoeal Disease and Research, Bangladesh (ICDDR,B). She also serves as chairperson of the Institute for developing Science and Health initiatives. Her scientific achievements lie in enteric infections and vaccines including Vibrio cholerae and enterotoxigenic Escherichia coli—major causes of severe diarrhea. She has also focused on studying the immune response in Helicobacter pylori infected people in Bangladesh and the responses in patients with typhoid fever as well as vaccinees. The Government of Bangladesh awarded her the Independence Award in 2023.
Joanne Liu is a Canadian pediatric emergency medicine physician, Associate Professor of Medicine at the University of Montreal, Professor of Clinical Medicine at McGill University, and the previous International President of Médecins sans Frontières. She was elected president during MSF's International General Assembly in June 2013.
Ebola vaccines are vaccines either approved or in development to prevent Ebola. As of 2022, there are only vaccines against the Zaire ebolavirus. The first vaccine to be approved in the United States was rVSV-ZEBOV in December 2019. It had been used extensively in the Kivu Ebola epidemic under a compassionate use protocol. During the early 21st century, several vaccine candidates displayed efficacy to protect nonhuman primates against lethal infection.
Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a global nonprofit partnership focused on supporting the development of new antibacterial products. Its mission is to strengthen the pipeline of vaccines, rapid diagnostics, antibiotics and non-traditional products to prevent, diagnose and treat life-threatening bacterial infections.
Kevin Outterson is a lawyer, a professor of law and the Austin B. Fletcher Professor Boston University School of Law (2023-present). He is also the executive director of Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator, a global non-profit partnership that supports companies developing new antibiotics, diagnostics, vaccines and other products to address drug-resistant bacterial infections.
Francine NtoumiPh.D., HDR, PvDz, FRCPedin is a Congolese parasitologist specializing in malaria. She was the first African person in charge of the secretariat of the Multilateral Initiative on Malaria (2006-2010). In recent years, she has become involved in research on other infectious diseases, including COVID-19.
Ogobara Doumbo was a Malian medical researcher at the University of Mali. He was recognised as a global leader in malaria research. He was the recipient of the Chevalier de l’Ordre National du Mali, Legion d'honneur and research award on Malaria in Africa.
Yves Lévy is a French physician researcher and professor of clinical immunology who served as CEO of the French Institute of Health and Medical Research (INSERM) from 2014 until 2018.
Jean-Jacques Muyembe is a Congolese microbiologist. He is the general director of the Democratic Republic of the Congo Institut National pour la Recherche Biomedicale (INRB). He was part of team at the Yambuku Catholic Mission Hospital that investigated the first Ebola outbreak, and was part of the effort that discovered Ebola as a new disease, although his exact role is still subject to controversy. In 2016, he led the research that designed, along with other researchers at the INRB and the National Institute of Health Vaccine Research Center in the US, one of the most promising treatment for Ebola, mAb114. The treatment was successfully experimented during recent outbreaks in the DRC, on the express decision of the then DRC Minister of Health, Dr Oly Ilunga, despite a prior negative advice from the World Health Organization.
Robert Steffen is an Emeritus Professor at the Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland and an adjunct professor at the University of Texas School of Public in Houston. He is an editor of the Journal of Travel Medicine.
Michael Joseph Ryan is an Irish epidemiologist and former trauma surgeon, specialising in infectious disease and public health. He is executive director of the World Health Organization's Health Emergencies Programme, leading the team responsible for the international containment and treatment of COVID-19. Ryan has held leadership positions and has worked on various outbreak response teams in the field to eradicate the spread of diseases including bacillary dysentery, cholera, Crimean–Congo hemorrhagic fever, Ebola, Marburg virus disease, measles, meningitis, relapsing fever, Rift Valley fever, SARS, and Shigellosis.
Sylvie Champaloux Briand is a French physician who is Director of the Pandemic and Epidemic Diseases Department at the World Health Organization. Briand led the Global Influenza Programme during the 2009 swine flu pandemic. During the COVID-19 pandemic, Briand launched the WHO Information Network for Epidemics which looked to counter the spread of COVID-19 misinformation.
The Strategic Advisory Group of Experts (SAGE) is the principal advisory group to World Health Organization (WHO) for vaccines and immunization. Established in 1999 through the merging of two previous committees, notably the Scientific Advisory Group of Experts and the Global Advisory Group by Director-General of the WHO Gro Harlem Brundtland. It is charged with advising WHO on overall global policies and strategies, ranging from vaccines and biotechnology, research and development, to delivery of immunization and its linkages with other health interventions. SAGE is concerned not just with childhood vaccines and immunization, but all vaccine-preventable diseases. SAGE provide global recommendations on immunization policy and such recommendations will be further translated by advisory committee at the country level.
The MIT Abdul Latif Jameel Clinic for Machine Learning in Health is a research center at the Massachusetts Institute of Technology (MIT) in the field of artificial intelligence (AI) and health sciences, including disease detection, drug discovery, and the development of medical devices. The MIT Jameel Clinic also supports the commercialization of solutions through grant funding, and has partnered with pharmaceutical companies, like Takeda and Sanofi, and philanthropies, like Community Jameel and Wellcome Trust, to forge collaborations between research and development functions and MIT researchers.
| International | |
|---|---|
| National | |
| Other | |
